发明名称 |
Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto |
摘要 |
A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome. |
申请公布号 |
US9546135(B2) |
申请公布日期 |
2017.01.17 |
申请号 |
US201514866212 |
申请日期 |
2015.09.25 |
申请人 |
Millendo Therapeutics, Inc. |
发明人 |
Hunt, III Stephen Warren;Phillips Martin Douglas;Matunas Robert;Chen Herman;Betancourt Aimesther;Uzarama Charles;Thibert Roch |
分类号 |
A61K9/50;C07C275/28;A61K9/20;C07C273/18;A61K31/17 |
主分类号 |
A61K9/50 |
代理机构 |
Seed IP Law Group LLP |
代理人 |
Seed IP Law Group LLP |
主权项 |
1. A solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride having a particle size distribution as follows: d(0.1) of about 2 μm, d(0.5) of about 12 μm, and a d(0.9) of about 49 μm. |
地址 |
Ann Arbor MI US |